Page last updated: 2024-08-17

quinoxalines and Mental Disorders

quinoxalines has been researched along with Mental Disorders in 33 studies

Research

Studies (33)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (36.36)	29.6817
2010's	21 (63.64)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Back, D; Belperio, P; Bondin, M; Crown, E; Marra, F; Mensa, FJ; Negro, F; Park, C; Pinsky, B; Talal, AH; Zhang, Z	1
Hviid, A; Pasternak, B; Svanström, H	1
Buggy, Y; Cornelius, V; Fogg, C; Kasliwal, R; Layton, D; Shakir, SA	1
Gibbons, RD; Mann, JJ	1
Beard, JD; Davis, RE; Hendrick, JP; Lee, T; Li, P; Mates, S; Peng, Y; Robichaud, AJ; Snyder, GL; Tomesch, J; Vanover, KE; Wennogle, LP; Yao, W; Zhang, Q; Zhu, H	1
Aitken, D; Clyde, M; Corran, B; Els, C; Pipe, A; Reid, RD; Tulloch, H	1
Rausch, R	1
Gunnell, D; Higgins, JP; Knipe, DW; Martin, RM; Thomas, KH	1
Harrison-Woolrych, M	1
Fazel, S; Gumpert, CH; Lichtenstein, P; Molero, Y; Zetterqvist, J	1
Cahill, K; Lancaster, T	1
Nadeem, SS; Pirmoradi, P; Roshan, S	1
Boyd, JW; Lasser, KE	1
Tavares, AR	1
Balvanz, TM; Magallon, HE; Mambourg, SE; Pham, RH; Purvis, TL	1
Dupont, P; Gillet, C; Guerin, M; Guillaumin, C; Kalamarides, S; Larinier, E; Meignan, C; Moreau, A; Perriot, J	1
Cantrell, FL; Clark, AK; Clark, RF; Kreshak, AA; Ly, BT	1
Richins, C	1
Burke, MV; Ebbert, JO; Hays, J; Wyatt, KD; Zirakzadeh, A	1
Mambourg, SE; Nelson, LA; Purvis, TL	1
Davies, S; Flammer, M; Hughes, J; Russ, C; Tonstad, S	1
Catz, SL; Deprey, M; Jack, L; Javitz, H; McAfee, T; McClure, JB; Richards, J; Swan, GE; Zbikowski, SM	1
Furberg, CD; Glenmullen, J; Moore, TJ	1
Ashton, J; Harrison-Woolrych, M	1
Jones, DL; Rankin, KV	1
Coster, TS; Graham, DJ; Meyer, TE; Moeny, D; Mosholder, AD; Ouellet-Hellstrom, RP; Taylor, LG; Williams, JR; Xie, S	1
Ahmed, AI; Ali, AN; Burger, DM; Härmark, LV; Kramers, C; Verhoeven, WM	1
Arnsten, JH; Bernstein, SL; Nahvi, S; Richter, KP; Wu, B	1
Dervaux, A; Kanit, M; Laqueille, X	1
Milbrandt, A; Ratcliffe, M; Smith, R; Spirling, LI; Stapleton, JA; Sutherland, G; Watson, L	1
Kuehn, BM	1
Perno Goldie, M	1

Reviews

5 review(s) available for quinoxalines and Mental Disorders

Article	Year
Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ (Clinical research ed.), 2015, Mar-12, Volume: 350 Topics: Aggression; Benzazepines; Depression; Humans; Mental Disorders; Quinoxalines; Risk Factors; Sleep Wake Disorders; Suicide; Suicide, Attempted; Tobacco Use Cessation Devices; Varenicline	2015
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. International journal of chronic obstructive pulmonary disease, 2009, Volume: 4 Topics: Benzazepines; Cardiovascular Diseases; Drug Labeling; Humans; Mental Disorders; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline	2009
Varenicline use in patients with mental illness: an update of the evidence. Expert opinion on drug safety, 2010, Volume: 9, Issue:3 Topics: Benzazepines; Evidence-Based Medicine; Humans; Limbic System; Mental Disorders; Mood Disorders; Patient Education as Topic; Quinoxalines; Smoking; Smoking Cessation; Suicide; Treatment Outcome; Varenicline	2010
Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug safety, 2010, Apr-01, Volume: 33, Issue:4 Topics: Adolescent; Adult; Aged; Benzazepines; Double-Blind Method; Female; Humans; Incidence; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Placebos; Quinoxalines; Randomized Controlled Trials as Topic; Risk; Sleep Wake Disorders; Smoking Cessation; Varenicline	2010
Neuropsychiatric adverse events of varenicline: a systematic review of published reports. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:1 Topics: Adult; Aged; Benzazepines; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Risk Assessment; Risk Factors; Smoking Cessation; Smoking Prevention; Time Factors; Varenicline; Young Adult	2013

Trials

2 trial(s) available for quinoxalines and Mental Disorders

Article	Year
Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial. Contemporary clinical trials, 2014, Volume: 38, Issue:2 Topics: Adult; Benzazepines; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Research Design; Smoking Cessation; Socioeconomic Factors; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Varenicline	2014
Smoking outcome by psychiatric history after behavioral and varenicline treatment. Journal of substance abuse treatment, 2010, Volume: 38, Issue:4 Topics: Adult; Behavior Therapy; Benzazepines; Combined Modality Therapy; Directive Counseling; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline	2010

Article

Year

Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial.

Contemporary clinical trials, 2014, Volume: 38, Issue:2

Topics: Adult; Benzazepines; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Research Design; Smoking Cessation; Socioeconomic Factors; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Varenicline

2014

Smoking outcome by psychiatric history after behavioral and varenicline treatment.

Journal of substance abuse treatment, 2010, Volume: 38, Issue:4

Topics: Adult; Behavior Therapy; Benzazepines; Combined Modality Therapy; Directive Counseling; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline

2010

Other Studies

26 other study(ies) available for quinoxalines and Mental Disorders

Article	Year
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. Journal of viral hepatitis, 2019, Volume: 26, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antidepressive Agents; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Mental Disorders; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Adherence and Compliance; Young Adult	2019
Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction (Abingdon, England), 2013, Volume: 108, Issue:7 Topics: Adult; Benzazepines; Bupropion; Denmark; Dopamine Uptake Inhibitors; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Proportional Hazards Models; Quinoxalines; Risk Factors; Smoking Cessation; Smoking Prevention; Treatment Outcome; Varenicline	2013
Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Drug safety, 2013, Volume: 36, Issue:7 Topics: Adult; Adverse Drug Reaction Reporting Systems; Benzazepines; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; England; Female; General Practice; Humans; Incidence; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Smoking Cessation; Varenicline	2013
Varenicline, smoking cessation, and neuropsychiatric adverse events. The American journal of psychiatry, 2013, Volume: 170, Issue:12 Topics: Adult; Aggression; Akathisia, Drug-Induced; Benzazepines; Bupropion; Depression; Female; Humans; Male; Mental Disorders; Nausea; Observational Studies as Topic; Psychomotor Agitation; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation; Suicidal Ideation; Suicide, Attempted; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline	2013
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. Journal of medicinal chemistry, 2014, Mar-27, Volume: 57, Issue:6 Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Biological Availability; Drug Discovery; Electroshock; Indicators and Reagents; Male; Mental Disorders; Nervous System Diseases; Quinoxalines; Quipazine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Recombinant Proteins; Schizophrenia; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship	2014
[Abstinence rates among varenicline are highest]. Medizinische Monatsschrift fur Pharmazeuten, 2014, Volume: 37, Issue:5 Topics: Benzazepines; Bupropion; Humans; Mental Disorders; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline	2014
Mental health effects of varenicline. BMJ (Clinical research ed.), 2015, Mar-17, Volume: 350 Topics: Benzazepines; Humans; Mental Disorders; Quinoxalines; Sleep Wake Disorders; Tobacco Use Cessation Devices; Varenicline	2015
Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ (Clinical research ed.), 2015, Jun-02, Volume: 350 Topics: Accidents, Traffic; Adolescent; Adult; Aged; Benzazepines; Cohort Studies; Crime; Epidemiologic Methods; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Suicide; Tobacco Use Cessation Devices; Varenicline; Young Adult	2015
ACP Journal Club. Review: Varenicline does not differ from placebo for adverse neuropsychiatric events. Annals of internal medicine, 2015, Jul-21, Volume: 163, Issue:2 Topics: Benzazepines; Humans; Mental Disorders; Quinoxalines; Sleep Wake Disorders; Tobacco Use Cessation Devices	2015
Varenicline (Chantix) warnings: risk versus benefit. The Medical letter on drugs and therapeutics, 2008, Jul-14, Volume: 50, Issue:1290 Topics: Benzazepines; Drug Partial Agonism; Humans; Mental Disorders; Nicotinic Agonists; Quinoxalines; Risk Assessment; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline	2008
Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Sep-01, Volume: 65, Issue:17 Topics: Adult; Alcoholism; Benzazepines; Depressive Disorder, Major; Humans; Male; Mental Disorders; Nervous System Diseases; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline	2008
Varenicline and smokers with mental illnesses. Lancet (London, England), 2008, Oct-04, Volume: 372, Issue:9645 Topics: Benzazepines; Humans; Mental Disorders; Patient Selection; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation; Varenicline	2008
Varenicline for tobacco dependence. The New England journal of medicine, 2009, Feb-12, Volume: 360, Issue:7 Topics: Benzazepines; Humans; Mental Disorders; Nicotinic Agonists; Quinoxalines; Smoking; Suicide; Tobacco Use Disorder; Varenicline	2009
Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:5 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Benzazepines; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Sex Factors; Smoking Cessation; Tobacco Use Disorder; Varenicline; Veterans	2009
[Tolerability profile of varenicline in current medical practice]. Presse medicale (Paris, France : 1983), 2010, Volume: 39, Issue:1 Topics: Adult; Benzazepines; Female; France; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Metabolic Diseases; Nervous System Diseases; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Skin Diseases; Smoking; Varenicline	2010
A retrospective poison center review of varenicline-exposed patients. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:12 Topics: Adolescent; Adult; Benzazepines; Child, Preschool; Databases, Factual; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Infant; Male; Medication Errors; Mental Disorders; Nicotinic Agonists; Poison Control Centers; Quinoxalines; Retrospective Studies; Smoking Cessation; Varenicline	2009
Regulation of smoking cessation drugs by the Food and Drug Administration. Food and drug law journal, 2009, Volume: 64, Issue:2 Topics: Benzazepines; Clinical Trials as Topic; Drug Approval; Drug Interactions; Government Regulation; Humans; Mental Disorders; Nicotinic Agonists; Product Surveillance, Postmarketing; Psychotropic Drugs; Quinoxalines; Smoking; Smoking Cessation; United States; United States Food and Drug Administration; Varenicline	2009
Thoughts and acts of aggression/violence toward others reported in association with varenicline. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:9 Topics: Adult; Aggression; Benzazepines; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Thinking; Varenicline; Violence	2010
Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug safety, 2011, Sep-01, Volume: 34, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; New Zealand; Nicotinic Agonists; Product Surveillance, Postmarketing; Prospective Studies; Quinoxalines; Sleep Wake Disorders; Smoking Cessation; Surveys and Questionnaires; Varenicline; Young Adult	2011
Treatment of nicotine dependence with Chantix (varenicline). Texas dental journal, 2011, Volume: 128, Issue:5 Topics: Adult; Benzazepines; Disclosure; Drug Interactions; Humans; Mental Disorders; Nausea; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Randomized Controlled Trials as Topic; Risk Assessment; Safety; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult	2011
Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction (Abingdon, England), 2013, Volume: 108, Issue:1 Topics: Adult; Aged; Benzazepines; Bupropion; Female; Hospitalization; Humans; Male; Mental Disorders; Middle Aged; Military Personnel; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Smoking Cessation; Tobacco Use Cessation Devices; United States; Varenicline; Young Adult	2013
Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness. Drug and alcohol dependence, 2013, Sep-01, Volume: 132, Issue:1-2 Topics: Benzazepines; Cardiovascular Diseases; Comorbidity; Data Interpretation, Statistical; Female; Humans; Longitudinal Studies; Male; Mental Disorders; Methadone; Middle Aged; Narcotics; Nicotinic Agonists; Opioid-Related Disorders; Prevalence; Primary Health Care; Quinoxalines; Smoking; Smoking Cessation; Socioeconomic Factors; Treatment Outcome; Varenicline	2013
Efficacy of varenicline for smoking cessation. JAMA, 2006, Dec-06, Volume: 296, Issue:21 Topics: Benzazepines; Humans; Mental Disorders; Quinoxalines; Smoking; Smoking Cessation; Varenicline	2006
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction (Abingdon, England), 2008, Volume: 103, Issue:1 Topics: Adult; Benzazepines; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Humans; London; Male; Mental Disorders; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome; Varenicline	2008
FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA, 2008, Mar-12, Volume: 299, Issue:10 Topics: Anticonvulsants; Benzazepines; Humans; Mental Disorders; Quinoxalines; Risk; Smoking Cessation; Suicide; United States; United States Food and Drug Administration; Varenicline	2008
Empowering dental hygienists: tobacco cessation resources. International journal of dental hygiene, 2008, Volume: 6, Issue:2 Topics: Benzazepines; Dental Hygienists; Humans; Mental Disorders; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Smoking Cessation; United States; United States Food and Drug Administration; Varenicline	2008